Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Ranolazine: a new approach to treating an old problem Reddy BM; Weintraub HS; Schwartzbard AZTex Heart Inst J 2010[]; 37 (6): 641-7Chronic angina pectoris affects millions of patients every year. During the past 2 decades, advances in medical therapy have led to substantial reductions in the symptoms of angina. Nonetheless, many patients continue to experience persistent angina that causes debilitating symptoms and lifestyle changes. Moreover, many current therapeutic agents cause side effects that can induce substantial morbidity on their own. In major clinical trials, the drug ranolazine has been shown to bring symptomatic relief to large numbers of patients who have chronic angina. Herein, we review the physiology of the sodium channel; the pharmacology of ranolazine; clinical trials that support use of the drug; recent evidence about ranolazine's therapeutic effect on diastolic heart failure, glycemic control, and atrial fibrillation and other arrhythmias; officially approved clinical indications; and avenues of future study.|Acetanilides/adverse effects/*therapeutic use[MESH]|Angina Pectoris/drug therapy[MESH]|Angina, Unstable/drug therapy[MESH]|Anti-Arrhythmia Agents/adverse effects/*therapeutic use[MESH]|Atrial Fibrillation/drug therapy[MESH]|Chronic Disease[MESH]|Evidence-Based Medicine[MESH]|Heart Diseases/*drug therapy[MESH]|Heart Failure, Diastolic/drug therapy[MESH]|Humans[MESH]|Myocardial Infarction/drug therapy[MESH]|Piperazines/adverse effects/*therapeutic use[MESH]|Practice Guidelines as Topic[MESH]|Ranolazine[MESH]|Sodium Channel Blockers/adverse effects/*therapeutic use[MESH]|Treatment Outcome[MESH] |
